Advertisement

Cardiovascular Disease in Diabetic Nephropathy

  • L. Lee Hamm
  • Tina K. Thethi
  • Kathleen S. Hering-Smith
Chapter

Abstract

Diabetes and chronic kidney disease lead to excess cardiovascular disease. Together these two entities have even more cardiovascular risk leading to excess morbidity and mortality. In fact, adverse cardiovascular outcomes are significantly more likely than end stage renal disease (ESRD) in patients with diabetic nephropathy. These diseases (diabetes, chronic kidney disease, and cardiovascular diseases) are growing major public health problems as illustrated by the prevalence and costs illustrated in Fig. 11.1. This chapter will review selected aspects of cardiovascular disease in patients with diabetic nephropathy. Because there is abundant literature in these areas, references are only selective and representative.

Keywords

Chronic Kidney Disease Glomerular Filtration Rate Diabetic Nephropathy Urinary Albumin United Kingdom Prospective Diabetes Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Seshasai SR, Kaptoge S, Thompson A, Di AE, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–41.PubMedCrossRefGoogle Scholar
  2. 2.
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143–421.Google Scholar
  3. 3.
    De BG, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis. 2003; 171(1):145–55.CrossRefGoogle Scholar
  4. 4.
    Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979;59(1):8–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434–44.PubMedCrossRefGoogle Scholar
  6. 6.
    Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22(2):233–40.PubMedCrossRefGoogle Scholar
  7. 7.
    Laguardia HA, Hamm LL, Chen J. The metabolic syndrome and risk of chronic kidney disease: pathophysiology and intervention strategies. J Nutr Metab. 2012;2012:652608. doi: 10.1155/2012/652608. Epub@2012 Feb 22.:652608.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    DeBoer MD. Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions. Nutrition. 2013;29(2):379–86.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–32.PubMedCrossRefGoogle Scholar
  11. 11.
    Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813–21.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154–69.PubMedCrossRefGoogle Scholar
  14. 14.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.PubMedCrossRefGoogle Scholar
  15. 15.
    Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–63.PubMedCrossRefGoogle Scholar
  16. 16.
    Patel UD, Young EW, Ojo AO, Hayward RA. CKD progression and mortality among older patients with diabetes. Am J Kidney Dis. 2005;46(3):406–14.PubMedCrossRefGoogle Scholar
  17. 17.
    Reinecke H, Trey T, Matzkies F, Fobker M, Breithardt G, Schaefer RM. Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. Kidney Int. 2003;63(2):696–701.PubMedCrossRefGoogle Scholar
  18. 18.
    Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012; 379(9811):165–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049–60.PubMedCrossRefGoogle Scholar
  20. 20.
    Astor BC, Shafi T, Hoogeveen RC, Matsushita K, Ballantyne CM, Inker LA, et al. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis. 2012;59(5):653–62.PubMedCrossRefGoogle Scholar
  21. 21.
    Shlipak MG, Matsushita K, Arnlov J, Inker LA, Katz R, Polkinghorne KR, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369(10):932–43.PubMedCrossRefGoogle Scholar
  22. 22.
    Plantinga LC, Crews DC, Coresh J, Miller III ER, Saran R, Yee J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5(4):673–82.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489–95.PubMedCrossRefGoogle Scholar
  24. 24.
    Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302–8.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Groop PH, Thomas MC, Moran JL, Waden J, Thorn LM, Makinen VP, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58(7): 1651–8.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2010;53(11):2312–9.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303(5):423–9.PubMedCrossRefGoogle Scholar
  28. 28.
    van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341–52.PubMedCrossRefGoogle Scholar
  29. 29.
    Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014;25(2):349–60.PubMedCrossRefGoogle Scholar
  30. 30.
    Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305(23):2432–9.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584–92.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393–408.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Wahl P, Xie H, Scialla J, Anderson CA, Bellovich K, Brecklin C, et al. Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease. Diabetes Care. 2012;35(5):994–1001.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Slinin Y, Ishani A, Rector T, Fitzgerald P, MacDonald R, Tacklind J, et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. Am J Kidney Dis. 2012;60(5): 747–69.PubMedCrossRefGoogle Scholar
  35. 35.
    Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169. doi: 10.1136/bmj.d4169.:d4169.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151(6):394–403.PubMedCrossRefGoogle Scholar
  37. 37.
    Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.PubMedCrossRefGoogle Scholar
  38. 38.
    Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.PubMedCrossRefGoogle Scholar
  39. 39.
    Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Herzog C, et al. US renal data system 2012 annual data report. Am J Kidney Dis. 2013;61(1 Suppl 1):A7, e1-A7, 476.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • L. Lee Hamm
    • 1
  • Tina K. Thethi
    • 2
    • 3
  • Kathleen S. Hering-Smith
    • 4
  1. 1.Dean’s Office, Tulane Medical SchoolNew OrleansUSA
  2. 2.Section of Endocrinology, Department of MedicineTulane University Health Sciences CenterNew OrleansUSA
  3. 3.Southeast Louisiana Veterans Health CareNew OrleansUSA
  4. 4.Section of Nephrology and Hypertension, Department of MedicineTulane University Health Sciences CenterNew OrleansUSA

Personalised recommendations